These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 15922661

  • 21. Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats.
    King RA, Smith RM, Krishnan R, Cleary EG.
    J Hypertens; 1992 Sep; 10(9):919-28. PubMed ID: 1328373
    [Abstract] [Full Text] [Related]

  • 22. Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition.
    Pelzer T, de Jager T, Muck J, Stimpel M, Neyses L.
    J Hypertens; 2002 May; 20(5):1001-6. PubMed ID: 12011662
    [Abstract] [Full Text] [Related]

  • 23. Moexipril and left ventricular hypertrophy.
    Chrysant GS, Nguyen PK.
    Vasc Health Risk Manag; 2007 May; 3(1):23-30. PubMed ID: 17583172
    [Abstract] [Full Text] [Related]

  • 24. Analysis of antihypertensive drugs in the heart of animal models: a proteomic approach.
    Lázaro A, Gállego-Delgado J, Osende JI, Egido J, Vivanco F.
    Methods Mol Biol; 2007 May; 357():45-58. PubMed ID: 17172677
    [Abstract] [Full Text] [Related]

  • 25. Contribution of bradykinin to the cardioprotective action of angiotensin converting enzyme inhibition in hypertension and after myocardial infarction.
    Ito K, Zhu YZ, Zhu YC, Gohlke P, Unger T.
    Jpn J Pharmacol; 1997 Dec; 75(4):311-8. PubMed ID: 9469636
    [Abstract] [Full Text] [Related]

  • 26. Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth.
    Grohé C, Kahlert S, Löbbert K, Neyses L, van Eickels M, Stimpel M, Vetter H.
    J Hypertens; 1998 Mar; 16(3):377-84. PubMed ID: 9557931
    [Abstract] [Full Text] [Related]

  • 27. Targeting pathological remodeling: concepts of cardioprotection and reparation.
    Weber KT.
    Circulation; 2000 Sep 19; 102(12):1342-5. PubMed ID: 10993849
    [No Abstract] [Full Text] [Related]

  • 28. Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension.
    Asmar R, Sayegh F, Tracz W, Hlawaty M, Olszowska M, Jourde M, Vincent M, Goujoun B, Maldonado J.
    Acta Cardiol; 2002 Feb 19; 57(1):31-2. PubMed ID: 11918132
    [No Abstract] [Full Text] [Related]

  • 29. Role of ACE inhibitors in hypertension with left ventricular hypertrophy.
    Richards AM, Nicholls MG, Crozier IG.
    Br Heart J; 1994 Sep 19; 72(3 Suppl):S24-32. PubMed ID: 7946799
    [No Abstract] [Full Text] [Related]

  • 30. Association between transforming growth factor-beta and hypertension.
    Lijnen PJ, Petrov VV, Fagard RH.
    Am J Hypertens; 2003 Jul 19; 16(7):604-11. PubMed ID: 12850397
    [Abstract] [Full Text] [Related]

  • 31. Influence of ACE-inhibition and mechanical unloading on the regulation of extracellular matrix proteins in the myocardium of heart transplantation candidates bridged by ventricular assist devices.
    Milting H, Kassner A, Arusoglu L, Meyer HE, Morshuis M, Brendel R, Klauke B, El Banayosy A, Körfer R.
    Eur J Heart Fail; 2006 May 19; 8(3):278-83. PubMed ID: 16309954
    [Abstract] [Full Text] [Related]

  • 32. Left ventricular hypertrophy: a new approach for fibrosis inhibition.
    Muiesan ML.
    J Hypertens; 2002 Apr 19; 20(4):611-3. PubMed ID: 11910293
    [No Abstract] [Full Text] [Related]

  • 33. Left ventricular hypertrophy in systemic hypertension. Benefits of its reversal.
    Nogueira JB.
    Arq Bras Cardiol; 1999 Jul 19; 73(1):103-12. PubMed ID: 10684146
    [No Abstract] [Full Text] [Related]

  • 34. Left ventricular hypertrophy: virtuous intentions, malign consequences.
    Pokharel S, Sharma UC, Pinto YM.
    Int J Biochem Cell Biol; 2003 Jun 19; 35(6):802-6. PubMed ID: 12676167
    [Abstract] [Full Text] [Related]

  • 35. Structural correlates of electrical remodeling in ventricular hypertrophy.
    Reddy HK, Wasson S, Koshy SK, Komatireddy R.
    Cardiovasc Res; 2003 Jun 01; 58(3):495-7. PubMed ID: 12798420
    [No Abstract] [Full Text] [Related]

  • 36. Influence of non-beta-adrenergic blocking drugs on left ventricular hypertrophy.
    Fouad-Tarazi FM.
    Am Heart J; 1987 Oct 01; 114(4 Pt 2):971-4. PubMed ID: 2959137
    [No Abstract] [Full Text] [Related]

  • 37. Can ACE inhibitors prevent chronic allograft failure?
    Danovitch GM.
    Am J Kidney Dis; 2001 Apr 01; 37(4):866-70. PubMed ID: 11273890
    [No Abstract] [Full Text] [Related]

  • 38. A pill for every ill.
    Swan L.
    Circulation; 2002 Apr 09; 105(14):e82; author reply e82. PubMed ID: 11940559
    [No Abstract] [Full Text] [Related]

  • 39. Preventing adult disease: windows of opportunity.
    Harrap SB.
    Clin Sci (Lond); 1998 Apr 09; 94(4):337-8. PubMed ID: 9640337
    [No Abstract] [Full Text] [Related]

  • 40. Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition.
    Duprez D.
    J Hypertens; 2002 May 09; 20(5):847-8. PubMed ID: 12011642
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.